ISCO (International Stem Cell) Total Current Assets: $3.81 Mil (As of Mar. 2026)


ISCO International Stem Cell Corp ISCO
24 GF Score
Price $0.16
GF Value $0.13
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is International Stem Cell Total Current Assets?

International Stem Cell ISCO -5.88% 24 Total Current Assets is $3.81 Mil as of Mar. 2026. GuruFocus rates ISCO with a GF Score™ of 24/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. International Stem Cell's total current assets for the quarter that ended in Mar. 2026 was $3.81 Mil.

International Stem Cell  (OTCPK:ISCO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

International Stem Cell's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.933-9.349+0.75 * 0.791+0.5 * 1.773
=-6.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell Total Current Assets Related Terms

International Stem Cell Total Current Assets Historical Data

* Premium members only.

The historical data trend for International Stem Cell's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell Total Current Assets Chart

International Stem Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.33 2.96 3.52 3.56 3.41

International Stem Cell Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.84 3.84 3.73 3.41 3.81
ISCO
24GF Score
International Stem Cell Corp ISCO
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

International Stem Cell Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

International Stem Cell's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.993+0.723+1.514+0.181
=3.41

International Stem Cell's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.933+0.843+1.773+0.264
=3.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $3.81 Mil mean?
International Stem Cell (ISCO) has a Total Current Assets of $3.81 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for International Stem Cell and its competitors.
Is International Stem Cell's Total Current Assets too high?
International Stem Cell's current Total Current Assets is $3.81 Mil. Overall, International Stem Cell has a GF Score™ of 24/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Total Current Assets compare to ZVSA and AXIM?
International Stem Cell's Total Current Assets of $3.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for International Stem Cell and its competitors. International Stem Cell's current Total Current Assets is $3.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.16 — trading 23.1% above its estimated fair value. The current Total Current Assets is $3.81 Mil. International Stem Cell's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Total Current Assets is $3.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.16 is trading 23.1% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Modestly Overvalued.

Key valuation signals for ISCO:

  • Total Current Assets: $3.81 Mil
  • GF Value™: $0.13 vs. price of $0.16 (23.1% above fair value)
  • GF Score™: 24/100 with 6 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
24GF Score

Get the complete analysis for ISCO

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price
$0.13
GF Value